ClinicalTrials.gg
CompletedNCT00120120Updated Sep 23, 2009

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy

A Phase 2/3 interventional study of Lenalidomide (CC-5013) in Radiculopathy, sponsored by Celgene Corporation. Completed at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-09-23.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 127 studies in Radiculopathy with a site in United States — 30 open to participants now, 38 under way, 2 of them phase 3. Radiculopathy · United States.

Enrollment
25th of 106
181 · median 78
Started
2005
with 2 others
Phase 2/3
5 of 127
none open now
Registered
5th of 127
by date

Among the 127 studies in Radiculopathy with a site in United States, this one is the 25th largest by enrollment of the 106 interventional ones that give a count, is one of 3 that started in 2005, is one of 5 in phase 2/3, and was the 5th registered.

Radiculopathy

484 studies on the registry are indexed under Radiculopathy; 145 are open to participants now.

Browse Radiculopathy studies →

Open to participants now

30 of the 127 studies in Radiculopathy with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 80 Radiculopathy studies recruiting now, 23 (29%) set no upper age limit and 49 (61%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Radiculopathy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of lenalidomide in the treatment of painful lumbar radiculopathy.

Read the detailed description

Study Duration: Pre-randomization Phase: 14 days; Treatment Phase: 12 weeks; Extension Phase: Ongoing; Total Study Duration: Up to 14 weeks + the duration of the extension phase

For each subject, the study consists of three phases: Pre-randomization phase (14 days), Treatment Phase (12 weeks) and an extension phase where subjects have the opportunity to receive lenalidomide treatment as long as benefit is derived from the drug. Subjects who complete all 12 weeks of the treatment phase may be eligible to initiate (subjects randomized to receive placebo in the treatment phase) or continue to receive lenalidomide therapy (subjects randomized to receive lenalidomide in the treatment phase) in the extension phase. Subjects may continue in the extension phase as long as a benefit is derived from the drug.

03

Conditions studied

  • Radiculopathy

Keywords

  • Radiculopathy
  • Back Pain
  • Lumbar Pain
  • CC-5013
  • Revlimid
  • Lenalidomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or greater at the time of signing the form
  • Clinical diagnosis of painful radiculopathy which is based on the presence of pain in the distribution of the sciatic nerve or L4, L5 or S1 dermatomes. The pain must be primarily in the lower leg and radiate to the ankle or foot.
  • History of painful radiculopathy involving one or both of the distal lower extremities for greater than or equal to 6 months
  • MRI or CT scan within the past 2 years or more recent if symptoms have changed
  • Positive straight leg raising (SLR) test in the index ipsilateral leg (pain radiating below the knee at an elevation of \<60 degrees). In the presence of bilateral leg pain, the leg with the most severe pain will be designated the index leg.
  • Screening (Visit 1): Radiculopathy PI-NRS score must be at least 5 on an 11-point (0-10) PI-NRS
  • Randomization (Visit 2): Average radiculopathy PI-NRS score for randomization purposes will be based on AM and PM assessments made during the 7 days prior to randomization:

    1. At least eight radiculopathy PI-NRS scores during this 7-day period are required and
    2. Average radiculopathy PI-NRS score during this period must be at least 5 on an 11-point (0-10) PI-NRS.
  • Stable doses of tricyclic antidepressants, AEDs, mexiletine hydrochloride, dextromethorphan, capsaicin, NSAIDs, opioids or other medications (including prn radiculopathy medication usage) that could affect symptoms of painful radiculopathy for at least 28 days prior to randomization (Visit 2).
  • Negative drugs of abuse screen (except drugs known to be prescribed for radiculopathy).
  • Women of (WCBP) must agree to practice complete abstinence from heterosexual intercourse or to use two methods of beginning 4 weeks prior to the start of study drug (Day 1) while on study drug (including dose interruptions) and 4 weeks after the last dose of study drug. The two methods of contraception must include one highly effective method (i.e. intrauterine device, hormonal [birth control pills, injections, or implants only if used in conjunction with a low-dose (81 mg/day) aspirin regimen], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). If a hormonal method (birth control pills, injections or implants) or IUD is not medically possible for the subject, two of the barrier methods will be acceptable.
  • Women of childbearing potential (WCBP) must have two negative pregnancy tests (sensitivity of at least 50 mlU/mL) prior to starting study drug treatment. The first test should be performed within 10-14 days and the second within 24 hours of starting study drug. Once treatment has started, it is recommended that subjects have weekly pregnancy tests during the first 4 weeks of treatment. Thereafter, subjects are required to have pregnancy testing every 4 weeks in females with regular menstrual cycles and every 2 weeks in females with irregular cycles.
  • Males (including those who have had a vasectomy) must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with WCBP while on study drug and for 4 weeks after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Pain localized in the low back or other sites that is a greater component of subject's total pain problem than lower leg and foot pain
  • Ankle or foot problems, which could interfere with the assessment of radiculopathy pain
  • Unstable lumbar spinal segment
  • Evidence of an acute operable lesion or tumor based on CT-scan or MRI results
  • Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac or neurological disease
  • Any medical condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Presence of a psychiatric diagnosis(es) that would impair reliable study participation
  • History of deep vein thrombosis (DVT) or stroke in the past 5 years
  • History of low back or lumbar spinal surgery
  • Documented metabolic or toxic peripheral neuropathies
  • Any other serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from understanding or signing the form
  • White blood cell count (WBC) \< 3.5 x 10/L at Visit 1
  • , (ALT), aspartate transaminase (AST) or alkaline phosphatase values more than two times the at Visit 1
  • Abnormal T3, T4 or TSH test value(s) at Visit 1 (An abnormal TSH level in the presence of normal T3 and T4 levels is acceptable).
  • More than 6 epidural injections within the 12 months prior to randomization (Visit 2).
  • Use of an epidural steroid injection within 28 days of randomization
  • Concurrent use of a spinal cord stimulator or intrathecal drug infusion device
  • Limited duration (planned termination during either the Pre-randomization or Treatment Phases) non-drug therapies (including physical therapy, acupuncture and chiropractic treatments) during the Pre-randomization and Treatment Phases of the study. Subjects may continue to do home exercises, if they have been a stable part of the subject's treatment regimen for at least 28 days prior to randomization.
  • Use of concomitant medications, which could increase the risk for developing DVT, except for steroid-based (oral, injectable, implantable) and hormone replacement therapies only if used in conjunction with a low-dose (81 mg/day) aspirin regimen
  • Use of oral corticosteroids (except for asthma inhalers and Medrol Dosepak) within 28 days prior to randomization
  • Concurrent use of thalidomide
  • Prior development of an allergic reaction/, a moderate or severe rash, or any desquamation while taking thalidomide.
  • Prior treatment with lenalidomide
  • Use of any other experimental drug or therapy within 28 days of the start of the Treatment Phase
  • Current pregnancy or lactation
  • History of poor compliance or the inability to comply with medical regimens or study requirements
  • Inability to use an electronic diary
  • Active litigation (i.e. any pending litigation or pending proceeding), compensation or disability issues related to painful radiculopathy (Subjects whose cases have been settled or finally decided are eligible)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    1

    Drug: Lenalidomide (CC-5013)

  • Experimental
    2

    Drug: Lenalidomide (CC-5013)

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in RAD pain intensity ratings using PI-NRS

    Time frame: baseline to week 12

Secondary outcomes

  1. Safety (type, frequency, severity, and relationship to study drug)

    Time frame: change from baseline

  2. Change from baseline in the PM PI NRS value

    Time frame: change from baseline

  3. Change from baseline in the AM PI NRS value

    Time frame: change from baseline

  4. Change from baseline inactivity level rating using an NRS

    Time frame: change from baseline

  5. Change from baseline in SLR angle of elevation without induced pain

    Time frame: change from baseline

  6. Change from baseline in the SF-MPQ total score and subscale scores

    Time frame: change from baseline

  7. Changes from baseline in the BPI score relative to baseline pain ratings and interference scales

    Time frame: change from baseline

  8. Changes from baseline in the POMS total mood score and six dimension subscale scores

    Time frame: change from baseline

  9. Change from baseline in the PDI score

    Time frame: change from baseline

  10. Change from baseline in the Modified Oswestry Low Back Pain Disability Questionnaire total score

    Time frame: change from baseline

  11. Patient global impression of change

    Time frame: change from baseline

07

Study locations

23 sites
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • Genova Clinical Research, Inc
    Tucson, Arizona 85741, United States
  • Loma Linda Institution
    Loma Linda, California 92354, United States
  • Space Coast Neurology
    Palm Bay, Florida 32905, United States
  • Gold Coast Research, LLC
    Weston, Florida 33331, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Rehab Institute of Chicago
    Chicago, Illinois 60611, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Johns Hopkins Pain Center
    Baltimore, Maryland 21205, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University Pain Mgmt Ctr
    St. Louis, Missouri 63141, United States
  • North Shore University Hospital
    Bethpage, New York 11554, United States
  • University of Rochester Medical CenterPain Services
    Rochester, New York 14642, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Carolinas Pain Institute, P.A. & the Center for Clinical Research, LLC
    Winston Salem, North Carolina 27103, United States
  • Research Institute of Greater Dayton
    Dayton, Ohio 45432, United States
  • Attn: Maryjane CerroneLehigh Valley Hospital
    Allentown, Pennsylvania 18103-6208, United States
  • Drexel University College of MedicineDepartment of Neurology Rm 7102
    Philadelphia, Pennsylvania 19102, United States
  • Texas Tech Medical Center Department of Anesthesiology
    Lubbock, Texas 79430, United States
  • KRK Medical Research
    Richardson, Texas 75080, United States
  • Fletcher Allen Healthcare for Pain Medicine
    South Burlington, Vermont 05403, United States
  • University of Virginia Pain Management Center
    Charlottesville, Virginia 22903, United States
  • Swedish Pain Services
    Seattle, Washington 98104, United States
08

References and documents

Publications

  • Manning DC, Gimbel J, Wertz R, Rauck R, Cooper A, Zeldis JB, Levinsky DM. A Phase II Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Lenalidomide in Lumbar Radicular Pain with a Long-Term Open-Label Extension Phase. Pain Med. 2017 Mar 1;18(3):477-487. doi: 10.1093/pm/pnw212. PubMed 27550953 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Oct 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2005
First posted
Jul 15, 2005
Start
Jan 2005
Primary completionActual
Oct 2007
CompletionActual
Nov 2007
Last update
Sep 23, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00120120
First posted
Jul 15, 2005
Start date
Jan 2005
Primary completion
Oct 2007
Completion
Nov 2007
Last update
Sep 23, 2009

Study contacts

Victor Sloan, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion